Menu
Tumor Targeted Superantigen (TTS) Enhances CAR-T Cell Activity Against Solid Tumors In Vivo
Sagi Y, Greenfeld D, Shany E, Azulay M, Bamany S and Shahar M
Poster presented at SITC Annual Meeting 2023
View PDF of the complete poster here
Combining Force Fields and Neural Networks for an Accurate Representation of Chemically Diverse Molecular Interactions
Alexey Illarionov, Serzhan Sakipov, Leonid Pereyaslavets, Igor V. Kurnikov, Ganesh Kamath, Oleg Butin, Ekaterina Voronina, Ilya Ivahnenko, Igor Leontyev, Grzegorz Nawrocki, Mikhail Darkhovskiy, Michael Olevanov, Yevhen K. Cherniavskyi, Christopher Lock, Sean Greenslade, Subramanian KRS Sankaranarayanan, Maria G. Kurnikova, Jeffrey Potoff, Roger D. Kornberg, Michael Levitt, and Boris Fain
See the full article here
Download PDF here
Safety and Preliminary Activity of Naptumomab Estafenatox (NAP) and Durvalumab in Patients with Advanced or Metastatic Solid Tumors Interim Results from a Phase 1b Trial (NCT03983954)
Ravit Geva, Salomon Stemmer, Ruth Perets, Corinne Maurice-Dror, Eitan Ben-Ami, Ari Raphael, Sanjeev Kumar, Ilana Lorber, Tal Hetzroni Kedem, Scott Z Fields, Marcel Rozencweig, and Talia Golan
View the complete poster here
Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading
Meir Azulay, Michal Shahar, Eitan Shany, Eti Elbaz, Sveta Lifshits, Marie Törngren, Adam Friedmann, Robert Kramer & Gunnar Hedlund
Published in the Journal of Translation Medicine
See the full article here
Download PDF here
Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors.
Sagi Y, Pinsker M and Shahar M
Poster presentation at SITC Annual Meeting 2021
View the complete poster here
Abstract: Sagi Y, Shahar M, Pinsker M. 576 Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors. Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.576 –
See the PDF here
Selective T cell Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Against the Tumor.
Azulay M, Lifshits S, Shany E, Friedmann A, Hedlund G and Shahar M.
Poster presentation at SITC Annual Meeting 2019.
View the complete poster here.
Naptumomab Estafenatox induces T cell recognition, turning anti-PD-1 unresponsive “cold” tumors into “hot” responsive tumors.
Azulay M, Lifshits S, Friedmann A, Hedlund G, Törngren M, Shahar M.
Poster presentation at AACR Annual Meeting 2018.
View the complete poster here.
Abstract: Meir Azulay, Sveta Lifshits, Adam Fridman, Gunnar Hedlund, Marie Törngren, Michal Shahar. Naptumomab Estafenatox induces T cell recognition, turning anti-PD-1 unresponsive “cold” tumors into “hot” responsive tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2712.
View the abstract here